Author:
Ritchlin Christopher T,Kavanaugh Arthur,Merola Joseph F,Schett Georg,Scher Jose U,Warren Richard B,Gottlieb Alice B,Assudani Deepak,Bedford-Rice Kathy,Coarse Jason,Ink Barbara,McInnes Iain B
Reference22 articles.
1. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies;Alinaghi;J Am Acad Dermatol,2019
2. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial;Mease;Arthritis Rheum,2005
3. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis;Singh;Arthritis Rheumatol,2019
4. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
5. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study;Mease;Ann Rheum Dis,2018